Purdue Puts Forth FDA Decisions As Defense To Massachusetts Opioid Suit

Purdue says Commonwealth is trying to hold it liable for conduct FDA has authorized; citing agency's approval of long-term use of OxyContin for chronic pain, company asks court to dismiss complaint.

OxyContin_1213430071_1200.jpg

Purdue Pharma LP is relying on the US FDA's opioid labeling decisions to squash a suit by the Commonwealth of Massachusetts alleging it improperly marketed its opioid medications for long-term therapy at high doses.

The company cites FDA approval of its OxyContin (oxycodone), Butrans (buprenorphine) transdermal system, and Hysingla (hydrocodone) extended release/long-acting opioid analgesics...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet